Table 1.

Patient characteristics.

Total number of patients	13
Median age, years (range)	15.5 (3–21)
Median weight, kg (range)	67.7 (15.2 – 110.9)
Median BSA, m2 (range)	1.8 (0.66–2.42)
Sex
Female	5 (38.5%)
Male	8 (61.5%)
Diagnoses
ALL	8 (61.5%)
AML	3 (23.1%)
CML	1 (7.7%)
Therapy-related MDS	1 (7.7%)
Median CD34+ cell dose, 10e6 cells/kg (range)	10.3 (5.6 −47.95)
Median neutrophil engraftment, days (range)	11 (8–12)
Median platelet engraftment, days (range)	15 (13–19)
Primary graft failure	1 (7.7%)
Secondary graft failure	1 (7.7%)
Relapse	3 (23.1%)
1-year OS	7 (53.8%)
aGVHD
Grade I	0
Grade II	2 (15.4%)
Grade III	1 (7.7%)
Grade IV	3 (23.1%)
cGVHD	2 (15.4%)
DLI administered	12 (92.3%)
Stem cell boost	3 (23.1%)
Median follow-up, years (range)	4.9 (0.1–8.9)